-+ 0.00%
-+ 0.00%
-+ 0.00%

Novo's CagriSema delivers superior weight loss versus tirzepatide in REIMAGINE 5 trial

Barchart·09/21/2026 05:24:00
Listen to the news

Bagsværd, Denmark, 21 September 2026 – Novo Nordisk today announced topline results from the phase 3 REIMAGINE 5 and REDEFINE 9 trials of once-weekly CagriSema (cagrilintide and semaglutide), an investigational product, and Novo's next innovation in weight management and type 2 diabetes. The findings were highlighted at Novo’s Capital Markets Day investor briefing.

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.